HIGHLIGHTS
- who: Chunyan Shi from the Shandong Cancer Hospital, China Tongji University, China have published the article: Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects, in the Journal: (JOURNAL)
- future: Investigation to determine the best treatment strategy for the simultaneous or continuous use of EGFR-TKIs or MEK inhibitors and ICIs in EGFR-mutant NSCLC is needed. More preclinical and clinical studies exploring the combination of ICIs and several other treatments such as antiangiogenesis chemotherapy novel ICIs radiotherapy antiCD47-SIRP-a anti-CD73- adenosine axis and B . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.